Profil
Mr. Matthew Fox is a Portfolio Manager at Bellevue Asset Management.
Prior to joining Bellevue, he was an analyst at EJF Capital, a US long/short equity and derivatives fund based in Washington, DC.
Together with one portfolio manager, he was responsible for investments in biotechnology and medical technology.
He began his professional investment career in 2003 at Rock Capital Partners in New York City, where he invested in biotechnology through the use of equities and options.
In 2005, he joined a portfolio manager dedicated to the biotechnology sector at Spectra Investment Group.
Mr. Fox graduated from Wesleyan University USA with a B.A.
in Neuroscience and Behavior.
Anciens postes connus de Matthew Fox
| Sociétés | Poste | Fin |
|---|---|---|
Bellevue Asset Management AG
 Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Analyst-Equity | 01/07/2009 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Bellevue Asset Management AG
Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Finance |
